Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

Core Viewpoint - Summit Therapeutics Inc. has announced a clinical trial collaboration with GSK plc to evaluate ivonescimab, a novel PD-1/VEGF bispecific antibody, in combination with GSK's investigational B7-H3 targeting antibody drug conjugate, risvutatug rezetecan, across multiple solid tumor settings, including small cell lung cancer [1] Group 1 - The collaboration aims to explore new mechanisms of action in cancer treatment [1]